


NS3861 fumarate

Cat. No.:	HY-110121
CAS No.:	216853-60-0
Molecular Formula:	C ₁₆ H ₁₈ BrNO ₄ S
Molecular Weight:	400.29
Target:	nAChR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (249.82 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.4982 mL	12.4909 mL	24.9819 mL
		5 mM	0.4996 mL	2.4982 mL	4.9964 mL
		10 mM	0.2498 mL	1.2491 mL	2.4982 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	NS3861 fumarate is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding K _i values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively ^[1] .
In Vitro	NS3861 fumarate displays the opposite β-subunit preference and a complete lack of activation at α4-containing receptors in HEK293 cell lines. NS3861 fumarate selectively activates α3- but not α4-containing nAChRs and it displays higher efficacy at the α3β2 receptor compared with the α3β4 receptor, with EC ₅₀ s of 1.7 and 0.15 μM for α3β2 and α3β4 receptor, respectively [1]. NS3861 fumarate shows high affinity and partial agonist properties in α3β4-expressed nAChRs ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kasper Harpsøe, et al. Molecular determinants of subtype-selective efficacies of cytosine and the novel compound NS3861 at heteromeric nicotinic acetylcholine receptors. *J Biol Chem.* 2013 Jan 25;288(4):2559-70.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA